← Global & Regional Health Technology Assessment
Papers in Global & Regional Health Technology Assessment
Page 2 · newest first
- Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation modelGlobal & Regional Health Technology Assessment · 2024
- Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare systemGlobal & Regional Health Technology Assessment · 2024
- A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunctionGlobal & Regional Health Technology Assessment · 2024
- The economic and social burden of congenital thrombotic thrombocytopenic purpura (cTTP) in ItalyGlobal & Regional Health Technology Assessment · 2024
- Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian studyGlobal & Regional Health Technology Assessment · 2024
- Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney diseaseGlobal & Regional Health Technology Assessment · 2024
- Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease networkGlobal & Regional Health Technology Assessment · 2024
- Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?Global & Regional Health Technology Assessment · 2024
- Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overviewGlobal & Regional Health Technology Assessment · 2024
- Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panelGlobal & Regional Health Technology Assessment · 2024
- Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databasesGlobal & Regional Health Technology Assessment · 2024
- Exploring the administrative burden faced by hematologists: a comprehensive study in ItalyGlobal & Regional Health Technology Assessment · 2024
- Early access programs for medicines: a reform proposal for the Italian National Health ServiceGlobal & Regional Health Technology Assessment · 2024
- Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)Global & Regional Health Technology Assessment · 2024
- How effective are prescriptive governance tools? Results from the application of AIFA notesGlobal & Regional Health Technology Assessment · 2024
- Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholdersGlobal & Regional Health Technology Assessment · 2024
- The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health ServiceGlobal & Regional Health Technology Assessment · 2024
- Patient-reported outcomes in epilepsy: a case study exploring their usage and impactGlobal & Regional Health Technology Assessment · 2024
- Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in ItalyGlobal & Regional Health Technology Assessment · 2024
- Regional administrative data and their role in planning, programming and controlling at regional levelGlobal & Regional Health Technology Assessment · 2024
- Heart failure and economic impact: an analysis in real clinical practice in ItalyGlobal & Regional Health Technology Assessment · 2024
- The socioeconomic burden of adult attention-deficit/hyperactivity disorder in SpainGlobal & Regional Health Technology Assessment · 2024
- The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical exampleGlobal & Regional Health Technology Assessment · 2024
- Regional Formularies in Italy: current state and future perspectivesGlobal & Regional Health Technology Assessment · 2024
- Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitisGlobal & Regional Health Technology Assessment · 2024
- HTA regulation: how is Italy moving?Global & Regional Health Technology Assessment · 2024
- Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in ItalyGlobal & Regional Health Technology Assessment · 2024
- Clinical and economic burden of peristomal skin complications: Activity Based Costing analysisGlobal & Regional Health Technology Assessment · 2024
- A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomasGlobal & Regional Health Technology Assessment · 2024
- Orphan drugs in Italy: availability and time-to-access at regional levelGlobal & Regional Health Technology Assessment · 2023
- Time to market access in Italy: duration of the P&R process for rare disease drugsGlobal & Regional Health Technology Assessment · 2023
- Unmet need: definitions, literature evidence and implications for HTAGlobal & Regional Health Technology Assessment · 2023
- Price and reimbursement of medicines when new indications are approved: the results of a survey on ISPOR Italy Rome Chapter membersGlobal & Regional Health Technology Assessment · 2023
- Cost-effectiveness of IMI/CIL/REL for the treatment of carbapenem non-susceptible Gram-negative bacterial infectionsGlobal & Regional Health Technology Assessment · 2023
- Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosisGlobal & Regional Health Technology Assessment · 2023
- Disability weights for castration-resistant prostate cancer: an empirical investigationGlobal & Regional Health Technology Assessment · 2022
- Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2022
- Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysisGlobal & Regional Health Technology Assessment · 2022
- New evidence in adjunctive treatment of focal-onset seizures in adults: a critical appraisalGlobal & Regional Health Technology Assessment · 2022
- Clinical opportunities and healthcare impact of optimal treatment in the post-ACS patientGlobal & Regional Health Technology Assessment · 2022
- Diagnostic and therapeutic approach to the ACS patientGlobal & Regional Health Technology Assessment · 2022
- Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutationsGlobal & Regional Health Technology Assessment · 2022
- A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in SpainGlobal & Regional Health Technology Assessment · 2022
- Cost-utility analysis of evolocumab in patients with ASCVD in ItalyGlobal & Regional Health Technology Assessment · 2021
- Evaluation of epidemiological and economic consequences due to the delay in treatment of hiv-positive patients caused by the covid-19 pandemicGlobal & Regional Health Technology Assessment · 2021
- Real-world data: how they can help to improve quality of careGlobal & Regional Health Technology Assessment · 2021
- Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in ItalyGlobal & Regional Health Technology Assessment · 2021
- Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly populationGlobal & Regional Health Technology Assessment · 2021
- Economic Impact of Therapeutic Choices: The Case of IncretinsGlobal & Regional Health Technology Assessment · 2021
- Budget Impact analysis of ponatinib for the management of patients with chronic myeloid leukemiaGlobal & Regional Health Technology Assessment · 2021